WebDec 12, 2024 · The investigation comparing the ASCT-ibrutinib arm with the ibrutinib-alone arm is ongoing, Dr Dreyling said. Overall survival results could not be evaluated … WebSunday, December 11, 2024: 4:45 PM. Martin Dreyling, MD 1, Michael Dickinson, MD 2, Joaquin Martinez Lopez 3 *, ... * signifies non-member of ASH. American Society of Hematology. 2024 L Street NW, Suite 900, Washington, DC 20036 Contact. Phone 202-776-0544 Toll Free 866-828-1231
Ibrutinib Induction/Maintenance Is Highly Effective for MCL
WebJan 6, 2024 · Martin Dreyling, MD, Department of Internal Medicine III, LMU University Hospital Munich, in Germany, discusses the outcomes of the phase 3 TRIANGLE study (NCT02858258) evaluating ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL). At the 2024 ASH Annual Meeting, Dreyling presented that patients can see … WebJan 5, 2024 · ASH 2024: Updated ELARA Trial Results of Tisagenlecleucel Therapy for Advanced Follicular Lymphoma. A study performed by Martin Dreyling, MD, of Ludwig … es der killer clown
ASH 2024 - CAR-T
WebJan 31, 2024 · Das ist eine herausragende, europäische Studie. Die Erhaltungstherapie mit Ibrutinib über 2 Jahre wird der neue Standard bei jüngeren Pat. nach Induktion mit Chemoimmuntherapie. Welche Rolle die Hochdosistherapie mit ASZT zukünftig in der Therapie des MZL spielt, ist unklar. Chemoimmuntherapie vs Hochdosistherapie mit … WebApr 24, 2024 · A 2024 Derby-Oaks Sire Double Could Make History. Of the 1,630 stallions who covered mares in North America in 2024, a grand total of up to 34 could have … WebDec 20, 2024 · Dreyling M, Dickinson M, Martinez Lopez J, et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated... finish hall buckley rental